News

Homebuilder donates $10,000 to MS Canada awareness fundraiser

Homebuilder Jayman Built is donating $10,000 to MS Canada ahead of the nonprofit’s annual MS Walk fundraiser to raise awareness of the disease, thanks to a successful social media campaign. The contribution adds to the nearly $1.5 million the Alberta, Canada, company has provided to the organization over the…

Altered immune B-cell metabolism drives inflammation in MS: Study

An abnormally active metabolism in immune B-cells can trigger the release of pro-inflammatory signaling molecules that drive further inflammation in multiple sclerosis (MS), a study found. Selectively blocking certain metabolic processes with a Bruton’s tyrosine kinase (BTK) inhibitor normalized B-cell metabolism and shifted their signaling to an anti-inflammatory state.

Use of mild-to-moderate DMTs predicts switching to other DMTs

People with multiple sclerosis (MS) who start treatment with a mild-to-moderate efficacy disease-modifying therapy (DMT) were more likely to switch to another DMT, an analysis of the German MS Registry finds. Starting a DMT between 2014 and 2017 was also a predictor of switching. Disease activity despite treatment…

Interferon beta corrects gene processing disrupted in MS: Study

Alternative splicing, a biological process that allows a single gene to code for multiple proteins, is extensively disrupted in immune cells isolated from untreated multiple sclerosis (MS) patients, and long-term treatment with interferon beta-based therapies largely corrects the defects, a study found. “Alternative splicing is a potential biomarker warning…

MS Canada seeks nationwide participation in awareness month

Canada has one of the world’s highest rates of multiple sclerosis (MS) in the world, and this month residents are being urged to come together to raise awareness of and funds for people affected by the neurodegenerative disorder. May is Multiple Sclerosis Awareness Month in Canada, and…

Committee favors approval of under-the-skin Ocrevus in Europe

A committee of the European Medicines Agency (EMA) is recommending the approval of a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) for people with multiple sclerosis (MS) in the European Union. The Committee for Medicinal Products for Human Use, known as CHMP, specifically recommended that this new formulation…

Nektar to develop NKTR-0165 for MS, autoimmune diseases

NKTR-0165, an antibody that targets the tumor necrosis factor receptor type 2 (TNFR2), will continue to be developed by Nektar Therapeutics as a candidate for treating multiple sclerosis (MS) and other autoimmune diseases. The experimental therapy was developed under a 2021 collaboration between Nektar and Biolojic…